Ambu A/S (AMBFF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ambu A/S (AMBFF) trades at $12.72 with AI Score 48/100 (Grade C). Ambu A/S is a Danish medical device company specializing in single-use endoscopes and other medical equipment. Market cap: $3.35B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for AMBFF: AMBFF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AMBFF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
AMBFF: the 3 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Ambu A/S (AMBFF) Healthcare & Pipeline Overview
Ambu A/S is a medical device company focused on single-use endoscopes and related products, serving hospitals, clinics, and rescue services globally. With a focus on innovation in visualization, anesthesia, and patient monitoring, Ambu aims to improve patient outcomes and streamline healthcare workflows, holding a significant position in the disposable endoscope market.
What Is the Investment Thesis for AMBFF?
Ambu A/S presents a notable research candidate due to its focus on single-use endoscopes, a market poised for growth driven by increasing awareness of infection control and workflow efficiency. With a market capitalization of $3.35B and a profit margin of 8.9%, Ambu demonstrates financial stability. Key growth catalysts include expanding its product portfolio and increasing market penetration in North America and Europe. However, potential risks include competition from established medical device companies and the need to maintain a high level of innovation to stay ahead of the curve. The company's beta of 1.40 suggests higher volatility compared to the market.
Based on FMP financials and quantitative analysis
AMBFF Key Highlights
Market capitalization of $3.35B indicates a substantial company size within the medical device industry.
- P/E ratio of 35.45 suggests investors are willing to pay a premium for Ambu's earnings, reflecting growth expectations.
- Gross margin of 55.9% demonstrates strong pricing power and efficient cost management.
- Dividend yield of 0.57% provides a small income stream for investors.
- Beta of 1.40 indicates the stock is more volatile than the market, potentially offering higher returns but also greater risk.
Who Are AMBFF's Competitors?
AMBFF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMFPF Amplifon S.p.A. | $11.21 | +0.00% | $2.97B | 38 |
| ANSLF Ansell Limited | $21.64 | +0.00% | $3.05B | 57 |
| BUGDF Bumrungrad Hospital Public Company Limited | $4.75 | +0.00% | $3.78B | 46 |
| BUHPF Bumrungrad Hospital Public Company Limited | $5.45 | +0.00% | $4.33B | 47 |
| GGNDF GN Store Nord A/S | $15.40 | +0.00% | $2.24B | 41 |
| TMDX TransMedics Group, Inc. | $90.85 | -3.32% | $3.14B | 79 |
| ITGR Integer Holdings Corporation | $125.21 | -0.07% | $4.25B | 71 |
| UFPT UFP Technologies, Inc. | $304.25 | -2.75% | $2.35B | 89 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AMBFF's Key Strengths?
Focus on single-use endoscopes addresses infection control concerns.
- Innovative product portfolio with continuous R&D efforts.
- Global presence and established distribution network.
- Strong brand reputation in the medical device industry.
What Are AMBFF's Weaknesses?
Reliance on single-use products may limit market reach.
- Higher price point compared to reusable endoscopes.
- Exposure to regulatory changes and healthcare policies.
- Dependence on key suppliers for raw materials and components.
What Could Drive AMBFF Stock Higher?
Expansion of single-use endoscope product line to address new medical procedures.
- Regulatory approvals for new medical devices in key markets (e.g., FDA approval in the U.S.).
- Increasing adoption of single-use endoscopes in hospitals and clinics worldwide.
- Strategic partnerships with healthcare providers and distributors to expand market reach.
- Growing awareness of infection control and the benefits of single-use devices.
What Are the Key Risks for AMBFF?
Competition from established medical device companies with greater resources.
- Regulatory changes and healthcare policies may impact product approvals and reimbursement rates.
- Economic downturns may reduce healthcare spending and demand for medical devices.
- Product recalls or safety concerns could damage reputation and lead to liability claims.
- Intellectual property infringement or patent disputes.
What Are the Growth Opportunities for AMBFF?
- Expansion in the U.S. Market: Ambu has a significant opportunity to expand its presence in the U.S. market, driven by the increasing adoption of single-use endoscopes. The U.S. endoscopy market is estimated to be worth billions of dollars, and Ambu's innovative products and strong sales force can help it capture a larger share. Timeline: Ongoing, with continuous efforts to increase market penetration.
- Product Innovation and Development: Ambu can drive growth by continuing to innovate and develop new products in the fields of visualization, anesthesia, and patient monitoring. The company's R&D efforts should focus on addressing unmet clinical needs and improving patient outcomes. Timeline: Ongoing, with new product launches planned regularly.
- Strategic Partnerships and Acquisitions: Ambu can accelerate its growth by forming strategic partnerships and acquiring complementary businesses. This can help the company expand its product portfolio, enter new markets, and gain access to new technologies. Timeline: Opportunistic, with potential deals evaluated on an ongoing basis.
- Penetration of Emerging Markets: Ambu has the opportunity to expand its presence in emerging markets such as China and India, where healthcare spending is growing rapidly. These markets offer significant growth potential for Ambu's products and services. Timeline: Long-term, with gradual expansion efforts over the next 5-10 years.
- Increase in Single-Use Endoscope Adoption: The increasing awareness of infection control and the benefits of single-use endoscopes are driving adoption in hospitals and clinics worldwide. Ambu can capitalize on this trend by educating healthcare providers about the advantages of its products and expanding its sales and marketing efforts. Timeline: Ongoing, with continuous efforts to promote the benefits of single-use endoscopes.
What Are AMBFF's Competitive Advantages?
- Proprietary technology in single-use endoscopes.
- Strong brand reputation for quality and innovation.
- Established distribution network and customer relationships.
- Intellectual property protection through patents.
What Does AMBFF Do?
Founded in 1937 and headquartered in Ballerup, Denmark, Ambu A/S develops, produces, and sells medical devices and solutions to hospitals, clinics, and rescue services worldwide. The company has evolved from its initial focus on resuscitation equipment to become a key player in single-use endoscopy. Ambu's product portfolio includes a range of endoscopy products such as bronchoscopes and monitors, as well as neurology products like EEG and EMG electrodes. Additionally, the company offers cardiology products, including ECG electrodes, and airway management and anesthesia products, such as video laryngoscopes and resuscitators. Ambu's single-use endoscopes are designed to eliminate the need for sterilization, reducing the risk of cross-contamination and improving workflow efficiency in healthcare settings. The company's global presence allows it to serve a diverse customer base with innovative and cost-effective medical solutions.
What Products and Services Does AMBFF Offer?
- Develops single-use endoscopes for various medical procedures.
- Produces and sells medical devices for visualization, anesthesia, and patient monitoring.
- Offers neurology products, including EEG and EMG electrodes.
- Provides cardiology products, such as ECG electrodes.
- Manufactures airway management and anesthesia products, including video laryngoscopes and resuscitators.
- Supplies extrication collars, CPR breathing barriers, and training manikins.
How Does AMBFF Make Money?
- Develops and manufactures medical devices in-house.
- Sells products directly to hospitals, clinics, and rescue services.
- Generates revenue through product sales and distribution agreements.
- Invests in research and development to create innovative medical solutions.
What Industry Does AMBFF Operate In?
Ambu A/S operates in the medical device industry, which is characterized by continuous innovation and stringent regulatory requirements. The global medical device market is expected to grow, driven by factors such as an aging population, increasing prevalence of chronic diseases, and technological advancements. Ambu's focus on single-use endoscopes positions it well to capitalize on the growing demand for infection control and efficient workflow solutions. Competitors include companies like Ambu, Inc. (AMFPF), which also offer medical devices and equipment. The industry is highly competitive, with companies constantly striving to develop new and improved products.
Who Are AMBFF's Key Customers?
- Hospitals and clinics
- Emergency medical services (EMS)
- Rescue services
- Healthcare providers
Company Profile
Ambu A/S operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Ballerup, DK. The company is led by CEO Britt Meelby Jensen. AMBFF has traded publicly since 2017.
Ambu A/S Financial Trajectory
Ambu A/S (AMBFF) reported $1.57B in revenue for Q1 2026, reflecting 1.3% growth compared to the prior quarter. The company recorded net income of $121.1M, with diluted EPS of $0.45. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, AMBFF averaged $0.45 in diluted EPS.
How Ambu A/S Is Valued
Ambu A/S carries a market capitalization of $3.35B, placing it in the mid-cap category. Relative to its peer group, AMBFF's quantitative score of 48/100 is roughly in line with the peer average of 46/100.
Key Financial Metrics
Return on equity for Ambu A/S stands at 7.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.3%, showing how much profit it generates from its asset base. AMBFF trades at a trailing price-to-earnings ratio of 36.69, above the Healthcare sector average of ~23x. Its free cash flow yield is 3.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.92 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.7%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Ambu A/S's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 9.82 places it in the safe zone, indicating low near-term bankruptcy risk.
Forward Outlook
Wall Street analysts project Ambu A/S revenue of about $6.51B for fiscal 2026, with EPS near $2.33. The estimate reflects 8 contributing analysts.
AMBFF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Ambu's innovative product pipeline, particularly within single-use endoscopes, continues to generate excitement within the medical community. This positions them well for future growth, similar to how Intuitive Surgical capitalized on robotic surgery early on.
- Recent insider buying activity suggests that those with the closest view of the company's prospects are optimistic about its future, which can often be a strong signal.
- The overall market sentiment within the social trading community reflects a belief in Ambu's long-term potential, fueled by its disruptive approach to medical devices.
- Ambu's focus on single-use devices aligns with the increasing emphasis on hygiene and infection control in healthcare, potentially making it a preferred choice for hospitals and clinics.
Bear Case
- Concerns linger about Ambu's ability to scale production efficiently to meet growing demand, potentially impacting profitability, as seen with other high-growth companies facing similar challenges.
- Negative sentiment surfaces in the community regarding increased competition in the single-use endoscope market, posing a threat to Ambu's market share.
- Some community members express skepticism about the long-term cost-effectiveness of single-use devices compared to traditional reusable alternatives, which could limit adoption.
- Recent market developments suggest a potential slowdown in hospital capital expenditure, which could negatively impact demand for Ambu's products, mirroring challenges faced by medical device companies during past economic downturns.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.57B | $121M | $0.45 |
| Q4 2025 | $1.55B | $118M | $0.44 |
| Q3 2025 | $1.46B | $115M | $0.43 |
| Q2 2025 | $1.51B | $123M | $0.46 |
Based on FMP financials and quantitative analysis
AMBFF Latest News
No recent news available for AMBFF.
AMBFF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AMBFF.
Price Targets
Wall Street price target analysis for AMBFF.
AMBFF MoonshotScore
What does this score mean?
The MoonshotScore rates AMBFF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Britt Meelby Jensen
CEO
Britt Meelby Jensen has served as the CEO of Ambu A/S, managing a workforce of 5,000 employees. Her career spans various leadership roles within the healthcare and pharmaceutical industries. She brings extensive experience in strategic development, commercial operations, and global market expansion. Jensen's background includes a strong focus on driving innovation and improving patient outcomes through advanced medical technologies. Her leadership is characterized by a commitment to sustainable growth and operational excellence.
Track Record: Under Britt Meelby Jensen's leadership, Ambu A/S has focused on expanding its single-use endoscopy portfolio and strengthening its global market position. Key achievements include driving revenue growth, enhancing operational efficiency, and fostering a culture of innovation within the company. Jensen has also overseen strategic acquisitions and partnerships to broaden Ambu's product offerings and market reach.
AMBFF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Ambu A/S (AMBFF) may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited regulatory oversight and reporting requirements compared to those listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier involves higher risks due to the potential for less transparency and liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Lower trading volume can lead to price volatility.
- Potential for fraud or manipulation is higher on the OTC Other tier.
- Lack of regulatory oversight may result in inadequate investor protection.
- Delisting risk if the company fails to meet minimum requirements.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Check for any regulatory actions or legal proceedings.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Established history of operations since 1937.
- Global presence and distribution network.
- Focus on innovative medical devices and solutions.
- Presence in the single-use endoscopy market.
- CEO with experience in the healthcare industry.
Common Questions About AMBFF (Healthcare)
What does the AI Score mean for AMBFF?
AMBFF holds an AI Score of 48/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Ambu A/S is a Danish medical device company specializing in single-use endoscopes and other medical equipment. The company operates globally, providing solutions for visualization, anesthesia, …
What does Ambu A/S do?
Ambu A/S develops, produces, and sells medical devices, primarily focusing on single-use endoscopes and related equipment. The company's products are used in visualization, anesthesia, and patient monitoring and diagnostics. Ambu's single-use endoscopes eliminate the need for sterilization, reducing the risk of cross-contamination and improving workflow efficiency in healthcare settings. The company serves hospitals, clinics, and rescue services worldwide, offering a range of innovative medical solutions.
What do analysts say about AMBFF stock?
Analyst coverage for AMBFF is limited due to its OTC listing. However, the company's focus on single-use endoscopes and its growth potential in the medical device market are generally viewed positively. Key valuation metrics, such as the P/E ratio of 35.45, suggest that investors have high expectations for future earnings growth. Analysts may also consider the company's financial stability, market position, and competitive landscape when evaluating the stock.
What are the main risks for AMBFF?
The main risks for AMBFF include competition from established medical device companies, regulatory changes and healthcare policies, economic downturns, product recalls or safety concerns, and intellectual property infringement. Additionally, the company's reliance on single-use products may limit its market reach, and its higher price point compared to reusable endoscopes could be a barrier to adoption in some markets.
How does Ambu A/S manage patent expiration risks?
Ambu A/S manages patent expiration risks through continuous innovation and development of new products and technologies. The company invests heavily in research and development to create innovative medical solutions and maintain a competitive edge. Ambu also seeks to protect its intellectual property through patents and other forms of legal protection.
What are the key growth opportunities for AMBFF in healthcare?
Key growth opportunities for AMBFF in healthcare include expanding its presence in the U.S. market, developing new applications for single-use endoscopes, forming strategic partnerships and acquisitions, and increasing adoption of single-use devices in emerging markets. The company can also drive growth by focusing on product innovation and addressing unmet clinical needs in the fields of visualization, anesthesia, and patient monitoring.
What are the key factors to evaluate for AMBFF?
Ambu A/S (AMBFF) holds an AI score of 48/100 (low). Ambu A/S presents a notable research candidate due to its focus on single-use endoscopes, a market poised for growth driven by increasing awareness of infection control and workflow efficiency. Not financial advice.
How frequently does AMBFF data refresh on this page?
AMBFF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven AMBFF's recent stock price performance?
Ambu A/S (AMBFF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on single-use endoscopes addresses infection control concerns. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC stock carries higher risk, do thorough due diligence.